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Summary 
 
Spinal muscular atrophy (SMA) is the most common 
motor neuron degenerative disease and is the principal 
genetic cause of infant mortality, affecting 1 in every 
6000 newborns.  The survival of motor neurons (SMN) 
gene has been implicated as the disease-causing gene 
in SMA, and it is deleted or mutated in over 98% of SMA 
patients. Our lab has pioneered research elucidating the 
functions of the SMN protein, which we have determined 
is a part of a large multi-protein complex (the SMN 
complex) that contains at least seven additional 
proteins, identified as Gemins 2-7.  The SMN complex is 
essential for the biogenesis of small nuclear RNA 
ribonucleoproteins (snRNPs), which are the major 
components of pre-mRNA splicing machinery.   We have 
determined that the genetic aberrations observed in 
SMA patients result in the depletion of functional SMN 
within cells.  Reduced levels of SMN correspond with a 
decreased capacity for snRNP assembly and 
widespread defects in splicing.  However, the 
mechanism by which SMN deficiency and universal 
defects in splicing lead to the cell-specific phenotype 
within motor neurons remains unclear.  Further research 
into the role of SMN in spinal muscular atrophy will 
potentially aid in the development of treatments for this 
devastating neurodegenerative disease.   
 
Introduction 
 
Spinal muscular atrophy (SMA) is a severe neuromuscular 
disorder characterized by the degeneration of motor neurons 
in the spinal cord, resulting in limb and trunk paralysis, 
muscular weakness, and muscular atrophy (1-3).  SMA is 
the second most common fatal autosomal recessive disorder 
after cystic fibrosis, affecting approximately 1 in every 6000 
newborns (1, 2), and it is classified as the most common 
genetic cause of childhood mortality (1, 2).  Mortality in SMA 
patients is most often the result of respiratory failure 
associated with progressive reductions in lung volume 
caused by paralysis and weakness of intercostal muscles 
(3).  The medical community has recognized three different 
forms of childhood SMA, which are differentiated based on 
severity and age of onset: Werdnig-Hoffmann disease (type-
I), the intermediate form (type-II), and Kugelberg- Welander 
disease (type-III), the mildest form (2,3).  Currently, 
treatments for SMA focus on managing the symptoms of the 
disease in an attempt to prolong life and improve the quality 
of life  of the patient; at the present time, there is no cure for 
SMA (3).   
The survival of motor neurons (SMN) gene has 
been implicated as the disease-causing gene in all three 
forms of the disease, and it is deleted or mutated in more  
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than 98% of SMA patients (2).  The gene is duplicated as an 
inverted repeat that is located on human chomosome 5 at 
5q13, and SMA results from homozygous deletions or 
mutations specifically in the telomeric copy of SMN (SMN1) 
(2, 4).  The centromeric copy of the gene, SMN2, produces 
mostly an alternatively spliced form of the SMN protein, 
which lacks the amino acids encoded by exon 7 and is 
unstable and rapidly degraded (2).  Hence, SMN2 can only 
partially compensate for aberrations in the SMN1 gene and 
therefore does not provide complete protection from SMA.   
The SMA phenotype is thus believed to be the result of SMN 
protein deficiency.  
The identification of the SMN gene as the disease 
gene of SMA has led to the intense study of the SMN protein 
and its functions within the cell.  In this review, we will 
examine important discoveries that have provided valuable 
insights into the cellular functions of SMN and its role in the 
pathogenesis of SMA.    
 
SMN and the SMN Complex 
 
The SMN protein is a polypeptide consisting of 294 amino 
acids that is expressed in all mammalian tissues and in all 
cell types of vertebrate organisms, but particularly high 
levels are expressed in motor neurons (5).  The presence of 
SMN is essential for cell viability in all model organisms 
studied thus far, including mice, C. elegans, and S. pombe 
(6-8).  SMN is found in both the cytoplasm and the nucleus 
of somatic cells and is highly concentrated in nuclear 
structures called gems (9).  Gems are similar in size and 
number to Cajal (coiled) bodies and are often located near or 
associated with these structures in the nucleus (9);  this 
suggests that gems and Cajal bodies may have related 
functions.  Cajal bodies are believed to be important in the 
metabolism of small nuclear ribonucleoproteins (snRNPs) 
and are therefore thought to contribute to pre-mRNA 
processing (10).  The discovery that SMN is associated with 
gems and Cajal bodies was one of the first clues that the 
SMN protein may be involved in snRNP processing and that 
SMA may arise from defects in RNA metabolism (9). 
 Further research into the SMN protein revealed 
that it is part of a large multi-protein complex (the SMN 
complex) that contains at least seven additional proteins, 
identified as Gemins2-8 (Figure 1) (11-16).  All of the 
Gemins colocalize with SMN in the cytoplasm, the 
nucleoplasm, and in gems (17).  SMN is always tightly 
associated with Gemin2, which was originally identified as 
SIP1 (SMN interacting protein 1) (11, 18). Interestingly, 
Gemin2 has significant sequence similarity with Brr1, a 
protein found in yeast that is necessary for the formation of 
snRNPs (18).  SMN also associates with Gemin3, a DEAD-
box RNA helicase that mediates the interaction of SMN with 
Gemin4 (12, 19).  Surprisingly, in addition to colocalizing 
with SMN in the cytoplasm and in gems, Gemin4 is also 
detected in the nucleolus (12).  Another integral component 
of the SMN complex is Gemin5, which is a large tryptophan-
aspartic acid (WD) repeat protein that binds SMN directly 
(13).  Gemins6 and 7 also associate with SMN as a part of 
the SMN complex, with Gemin7 facilitating the interaction of 
Gemin6 with the SMN complex (14-15).  A protein of 
unknown function, Gemin8, interacts directly with the 
heterodimer consisting of Gemins6 and 7 and is believed to 
be the final protein constituent of the SMN complex (16).    
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Figure 1. The SMN Complex and Its Functions  As depicted on the left, the SMN complex is a large, oligomeric multi-protein complex.  The complex 
consists of SMN as well as at least seven other proteins shown as Geminsβ.  For simplicity, the SMN complex is shown here as a dimmer.  There are 
several proteins that directly interact with the SMN complex, and these interactions are the basis of the complex’s numerous intracellular functions 
associated with RNA metabolism.  Specifically, the SMN complex has an essential function in snRNP assembly and premRNA splicing, which are 
mediated by its interactions with Sm proteins and snRNAs.  Additionally, the complex binds to the proteins fibrillarin and GAR1 and thus has a role in 
snoRNP biogenesis.  Finally, the complex interacts with RNA helicase A and therefore contributes to RNA polymerase II transcription.  Adapted from 
Battle et al., 2006. 
 
Functions of the SMN Complex 
 
In order to elucidate the molecular mechanisms that lead to 
the development of SMA, it was first necessary to identify 
the cellular functions of the SMN protein and the SMN 
complex.  Through extensive research, we have determined 
that SMN is involved in a multitude of intracellular processes, 
and that the SMN complex has a fundamental role in cellular 
RNA metabolism (Figure 1). 
 
snRNP Assembly and Pre-mRNA Splicing 
Our investigations of the cellular functions of SMN 
demonstrated that it is essential for the assembly of 
spliceosomal small nuclear ribonucleoproteins (snRNPs) 
(11, 14, 17-18, 20-23, 26). snRNPs are the major 
components of the spliceosome, the machinery responsible 
for carrying out pre-mRNA splicing (21). The biogenesis of 
snRNPs is a complex process that requires multiple steps in 
both the cytoplasm and the nucleus (22).  Each spliceosomal 
snRNP consists of one or two small nuclear RNAs 
(snRNAs), several proteins specific to individual snRNAs, 
and a set of seven common proteins called Sm proteins (21).  
The major snRNAs utilized in snRNP formation are identified 
as U1, U2, U5, and U4/6 (21).  In the cytoplasm, the Sm 
proteins form a seven-membered ring around a specific 
sequence on each snRNA called the Sm site, thus forming 
the Sm core (21-23).  This is followed by hypermethylation of 
the 5’ cap to form the 2,2,7-trimethyl guanosine cap. (22).  
The Sm core and the methylated cap help recruit the 
molecules required for transporting the snRNPs into the 
nucleus, where they function in splicing (21). 
Our research has led to numerous important 
findings that have provided evidence that the SMN complex 
is directly involved in the biogenesis of spliceosomal 
snRNPs. First, we found that the SMN complex interacts 
directly with both spliceosomal snRNP (Sm) proteins and 
spliceosomal snRNAs (11, 18). SMN interacts with the 
arginine- and glycine-rich (RG) domains of Sm proteins via 
its carboxyl-terminal YG domain (18).  The association of the 
SMN complex with the Sm proteins is enhanced by the 
methylation of specific arginines within the RG domains by 
the mehtylosome/PRMT5 complex (24).  Each of the 
Gemins, except Gemin2, directly binds to Sm proteins, as 
well (11-16).  In the cytoplasm, the SMN complex assembles 
Sm proteins onto the Sm site of snRNAs in an ATP-
dependent reaction, thus forming the Sm core (14, 24).  
Importantly, we found that the extent of Sm core assembly 
on snRNAs is directly proportional to the amount of SMN 
protein in the cell (25).   
Independent of its interactions with Sm proteins, 
the SMN complex also binds directly to snRNAs (14, 17, 26-
28). We have determined that Gemin5 is the specific 
component of the complex that binds and identifies snRNAs 
and allows the SMN complex to assemble them into snRNPs 
(29).  Additionally, we have identified specific sequences and 
structural features that are required for binding of the SMN  
complex to snRNAs (27-28).  The minimum requirements for 
binding of the SMN complex to the snRNAs are the Sm site 
as well as a SMN complex binding region (28).  For all but 
one of the snRNAs, the SMN complex binding domain 
consists of at least one stem-loop immediately 3’ of the Sm 
site (28).  In addition, the SMN complex specifically 
recognizes the first adenosine and the first and third uridines 
of the Sm site in all snRNAs (26).  These characteristics 
constitute a code that is recognized by the SMN complex 
and specifies which cellular RNAs are snRNAs that should 
be utilized for snRNP assembly (26). 
The SMN complex performs an essential function 
within the cell by ensuring that Sm cores assemble only on 
the correct RNA targets (14). The SMN complex 
accomplishes this by identifying the snRNAs required for 
snRNP assembly based on the specific sequences and 
structural features described above (26).  Moreover, the 
SMN complex binds the Sm proteins so that there are no 
free proteins that can assemble outside of the SMN complex 
(14).  The bound Sm proteins are therefore only capable of 
assembling an Sm core on RNAs that also bind to the SMN 
complex (14).  The high specificity of snRNA binding to the 
SMN complex ultimately results in the delivery of Sm 
proteins only on the appropriate snRNAs (14).  In preventing 
the nonspecific assembly of Sm cores on random RNAs, the 
SMN complex serves as a specificity factor that ensures that 
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only the correct snRNPs are formed, which is a vital function 
within cells. 
Through extensive research, we have discovered 
additional evidence supporting the role of the SMN complex 
in snRNP biogenesis.  For example, inhibition of the SMN 
complex interferes with the formation of snRNPs from Sm 
proteins and spliceosomal snRNAs and disrupts the import 
of the mature snRNP into the nucleus (11, 30). Moreover, 
the SMN complex is associated with snRNPs throughout 
their cytoplasmic assembly pathway, which suggests that it 
may have multiple functions throughout this process (31). 
The complex binds newly exported snRNAs and remains 
associated with the snRNPs during Sm core assembly, 
hypermethylation of the 5’ cap, and binding to the machinery 
required for reimport of the snRNP into the nucleus (31).  
These findings provide further support for the hypothesis that 
the SMN complex is essential for snRNP biogenesis in the 
cytoplasm. 
Furthermore, SMN is necessary for snRNP 
function and is required for pre-mRNA splicing in the nucleus 
(30). Wild-type SMN simulates splicing in vitro, whereas 
dominant-negative SMN mutants inhibit pre-mRNA splicing 
(30).  Similarly, the addition of anti-SMN antibodies to 
nuclear extracts inhibits splicing  (30);  a role for SMN in 
splicing is also suggested by its interaction with a family of 
hnRNP proteins, referred to as hnRNP Q proteins, which are 
components of the spliceosome and are required for efficient 
pre-mRNA splicing in vitro (32).  Although these findings 
indicate a functional role for the SMN complex in pre-mRNA 
splicing, it is unclear whether it is directly or indirectly 
involved in the process.  It is possible that the function of 
SMN in splicing may be secondary to its function in snRNP 
biogenesis (32). However, we hypothesize that SMN 
facilitates pre-mRNA splicing by regenerating or recycling 
snRNPs in the nucleus (30).  Based on these data, we 
conclude that the SMN complex has a fundamental role in 
snRNP assembly and pre-mRNA splicing and is therefore 
vital for the production of mature mRNA and overall cellular 
function. 
 
Additional Functions of the SMN Complex 
Through the course of our studies, we have identified 
several additional functions for the SMN complex in RNA 
metabolism.  For example, SMN binds directly to fibrillarin 
and GAR1, which are proteins associated with the two 
different classes of small nucleolar ribonucleoproteins 
(snoRNPs) that are involved in the posttranscriptional 
processing of ribosomal RNA (33).  Overexpression of a 
dominant-negative mutant of SMN causes massive 
reorganization of snoRNPs and inhibits transcription within 
the nucleolus (33). These findings indicate that the SMN 
complex is involved in snoRNP assembly and metabolism 
and may suggest that the SMN complex is necessary for the 
biogenesis and function of a diverse array of 
ribonucleoprotein complexes. 
The SMN complex also associates with RNA 
helicase A (RHA), a DEAH box RNA helicase that binds 
RNA polymerase II (34).  Expression of the dominant-
negative SMN∆N27 produces a drastic rearrangement of 
RNA polymerase II and RHA within the nucleus and results 
in the inhibition of transcription by RNA polymerases I and II 
(34). These findings suggest that the SMN complex may 
have a role in transcription, particularly in the assembly of 
the RNA polymerase II transcription and processing 
machinery (34).   
 
The Role of SMN in SMA 
 
Spinal muscular atrophy is caused by genetic deletions and 
mutations in the SMN1 gene that result in the depletion of 
functional SMN protein within cells (Figure 2) (2, 5).  Studies 
of cells derived from SMA patients have shown that the 
severity of SMA phenotypes is inversely correlated with the 
amount of SMN protein in these cells (5).  Individuals 
affected by the most severe form of SMA (type-I) have 
barely detectable levels of the SMN protein in various cell 
types, including motor neurons (5, 35).  In SMA, reduced 
levels of SMN correspond with defects in RNA metabolism 
and RNP biogenesis (19-20, 25, 30, 36).  
 
Defects in snRNP Assembly and Splicing 
SMA patients with deletions and mutations in the SMN1 
gene produce SMN proteins that are not functional, resulting 
in defects in snRNP assembly and pre-mRNA splicing (19-
20, 25, 30, 36).  Through the course of our research, we 
have determined that mutations in the SMN protein interfere 
with its ability to oligomerize, as demonstrated by a 
decreased capacity for SMN from SMA patients to interact 
with Gemin3 (19, 35).  This indicates that SMN mutants may 
have a reduced ability to form the complete SMN complex, 
which may contribute to the functional deficits observed in 
SMA patients.   
We have also found that mutant SMN proteins 
derived from SMA patients are defective in binding to Sm 
proteins and associating with snRNPs (20).  Additionally, we 
have established that the reduction of SMN protein levels in 
cells diminishes their ability to produce snRNPs and that the 
rate of snRNP biogenesis is significantly reduced in cells 
with low levels of SMN (25).  This is consistent with the 
finding that cellular extracts from SMA patients have a lower 
capacity for snRNP assembly that is directly proportional to 
the reduction of SMN protein in these cells (25).  Due to its 
role as a specificity factor for the assembly of snRNPs, it is 
also possible that SMN protein deficiency also results in the 
nonspecific binding of Sm proteins to RNAs, which would 
ultimately result in the formation of aberrant RNPs (14).  
These findings are particularly significant because they 
suggest that snRNP assembly may provide a molecular 
biomarker for SMA, which could aid in clinical trials, the 
development of drug therapies, and investigations into the 
disease pathology (37). 
Our studies have also revealed a link between 
SMN deficiency in SMA and defects in pre-mRNA splicing.  
Importantly, SMN mutants found in SMA patients cannot 
stimulate splicing and therefore lack the ability to regenerate 
splicing machinery (30).  Furthermore, we recently 
discovered that SMN deficiency in mice comparable to that 
which occurs in severe SMA causes cell type-specific 
disruptions in the repertoire of snRNAs and results in 
widespread defects in pre-mRNA splicing (36).  Interestingly, 
the splicing defects were observed in numerous different 
mRNAs from multiple tissues of the SMA mice models (36).  
These surprising discoveries support the hypothesis that the 
SMN complex is a major factor in RNA metabolism and 
splicing regulation and provide evidence that SMA is a 
general splicing disease that does not exclusively affect 
splicing in motor neurons (36). 
 
SMN Deficiency and Effects in Motor Neurons 
The mechanism by which SMN deficiency leads to the cell-
specific phenotype within motor neurons has not been 
established, although some lines of evidence provide 
insights into this phenomenon.  In humans, the small amount 
of full length SMN produced by SMN2 is sufficient for viability 
of all cells except motor neurons, which suggests that motor 
neurons are particularly sensitive to SMN reduction (5).  This 
observation gives rise to the possibility that SMN may have 
unique functions in motor neurons, which has been 
supported by numerous findings in other laboratories (38-
40).  One recent discovery was that the axonal-SMN protein, 
  78	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The Role of SMN Deficiency in SMA: A model of the normal function of SMN in snRNP formation and pre-mRNA splicing in healthy 
individuals (top) and the functional defects observed in spinal muscular atrophy (bottom).  In SMA, SMN deficiency leads to decreased binding of SMN 
to Sm proteins and snRNA, which results in an inability to form snRNPs and defective splicing of pre-mRNA.  This produces the SMA phenotype, which 
is characterized by degeneration of motor neurons in the spinal cord.  The mechanism by which universal defects in splicing lead to attrition of motor 
neurons specifically is still not understood, although it is hypothesized that cell type-specific differences in splicing defects may provide a possible 
explanation. 
 
 
a protein isoform produced from the SMN gene, is 
selectively expressed in developing motor neurons, is 
involved in axonogenessis, and is mainly localized in axons 
(40).  These findings could potentially explain the 
physiological effects of SMN deficiency in SMA patients 
since the depletion of the axonal-SMN protein isoform in 
motor neurons may have dramatic effects on their survival 
(40).  Additional research has demonstrated that SMN also 
plays a role in axonal growth, neuromuscular junction 
formation, and the transport of RNA along axons (41-42).  
Defects in any of these processes as a result of SMN 
deficiency in SMA could result in the selective death of motor 
neurons.  
Based on our current understanding of SMN 
function, however, it is reasonable to conclude that defects 
in RNA metabolism contribute to disease pathogenesis. 
Furthermore, the discovery that SMN deficiency causes 
tissue-specific perturbations in snRNAs and splicing 
suggests a possible explanation for the selective 
degeneration of motor neurons, which may experience more 
defects in splicing than other cell types (36). Low levels of 
SMN in SMA may therefore result in specific defects in RNA 
processing within motor neurons that disrupt their 
development and survival (36).  The identification of specific 
aberrations in RNA metabolism and pre-mRNA splicing 
within motor neurons will provide further support for this 
hypothesis and thus will likely be one of the focal points of 
future research in the field.   
 
Discussion 
 
Since the discovery in 1995 that mutations and deletions in 
the survival of motor neurons (SMN) gene cause spinal 
muscular atrophy (2), there have been profound advances in 
our understanding of the SMN protein and its role in SMA;  
namely, we have determined that SMN exists as a part of a 
multi-protein complex (the SMN complex), which has an 
essential role in pre-mRNA splicing and the assembly of 
snRNPs (11, 14, 17, 30).  Furthermore, we have established 
that SMA pathogenesis is caused by drastic reductions in 
SMN protein levels, resulting in defects in SMN complex 
function (19-20, 25, 30).  Importantly, we have also found 
that SMN deficiency causes cell type-specific changes in 
snRNP assembly and splicing, which may help explain the 
restricted death of motor neurons in SMA (36).  Hence, our 
studies have provided valuable insights into the molecular 
functions of the SMN protein in cells, the cellular pathways 
that are affected by decreased expression of functional 
SMN, and the mechanisms that may be contributing to the 
selective degeneration of motor neurons.  
Moreover, through the recognition that SMA is 
caused by SMN protein deficiency, our work has provided 
innovative treatment options for SMA, such as the 
development of agents that increase the availability of SMN 
(3).  Pharmaceuticals that could potentially enhance SMN2 
transcription, for example, could help compensate for 
mutations in the SMN1 gene by providing more functional 
SMN protein (3). Additional approaches to developing 
prospective therapeutic intervention in spinal muscular 
atrophy include methods used in other neurodegenerative 
diseases, such as gene therapy and cell replacement 
therapy (3).  Further research and the identification of the 
specific molecular pathways contributing to SMA should 
continue to pave the way for the development of new 
therapeutic approaches for treating this devastating 
neurodegenerative disease. 
Despite these major advancements, however, 
numerous questions about SMN and its involvement in SMA 
pathogenesis remain unanswered, such as the specific 
factors that result in the motor-neuron selective phenotype 
and the molecular basis for widespread splicing defects 
caused by SMN deficiency.  Ideally, elucidating the 
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remaining areas of inquiry through continued research will 
provide additional therapeutic targets for SMA as well as 
fundamental knowledge regarding motor neuron biology and 
pathology.   
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